Azacitidine Injection, Powder, Lyophilized, For Solution
Product Images NDC 71288-115
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Azacitidine (NDC 71288-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (Aza03 0003 02)
The text represents a statistical analysis showing a Log-Rank test result (p=0.0001) with Hazard Ratio (HR) of 0.58 and 95% confidence interval (Cl) from 0.43 to 0.77. The table shows the number of deaths and patients at risk for two different treatments (Aza and CCR) over time in months. The Aza had a higher number of patients at risk than the CCR treatment.*
Figure (Aza03 0003 03)
Figure (Aza03 0003 04)
Azacitidine for Injection is a cytotoxic agent and is available in a single-dose vial containing 100mg of azacitidine and 100mg of manniol. Before using, refer to the prescribing information for proper dosing and administration. Any unused medication should be safely discarded and kept away from children. This sterile, non-pyrogenic, and preservative-free medication should be stored between 20°C to 25°C or 68°F to 77°F with excursions allowed between 15°C to 30°C or 55°F to 8°F. The container closure is not made with natural rubber latex. Produced by Meitheal Pharmaceuticals, the Azacitidine for Injection carries the NDC71288-415-30 and NOC 7128811530 Beauty numbers.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.